Rivoglitazone

Drug Profile

Rivoglitazone

Alternative Names: CI 1037; CS-011; DE-101; R 119702; Rivo

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Daiichi Sankyo Company
  • Developer Daiichi Sankyo Company; Santen Pharmaceutical
  • Class Antihyperglycaemics; Small molecules; Thiazolidinediones
  • Mechanism of Action Epithelial cell modulators; Peroxisome proliferator-activated receptor gamma agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Dry eyes; Type 2 diabetes mellitus

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 02 Nov 2011 Phase-II clinical trials in Dry eyes in USA (Ophthalmic)
  • 02 Aug 2011 Santen completes phase I/II development in Dry eyes in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top